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We present the design, synthesis, characterization and biological evaluation of new ferrocenyl and ruthenocenyl derivatives of the 
organic antimalarial mefloquine, a drug also known for its antischistosomal activity. The two metallocenyl derivatives prepared (3 and 
4) demonstrated comparable activity to mefloquine against adult-stage Schistosoma mansoni in vitro. Importantly, both compounds 
were found to have lower toxicity in all cell lines than mefloquine itself. Administration of a 200 mg/kg oral dose of 3 and 4 to S. 
mansoni-infected mice did not significantly reduce worm burden, contrary to mefloquine. 
Introduction 
Schistosomiasis is a neglected tropical disease, that affects an estimated 190 million individuals worldwide, mostly children in 
rural areas of Sub-Saharan Africa.
1
 It is caused by an infection of parasitic worms from the Schistosoma genus, where 
Schistosoma haematobium (which causes urinary schistosomiasis) as well as S. mansoni and S. japonicum (which cause intestinal 
schistosomiasis) are the most prevalent species that infect humans.
2
 Individuals become infected when they come into contact 
with freshwater contaminated by free-swimming cercarial forms of the parasite, which enter the host via skin penetration. They 
migrate via blood circulation first to the lungs and then to the liver, where they mature and sexually pair. They finally move to 
reside in the veins of the mesenteries (intestinal schistosomiasis) or the urogenital plexus (urinary schistosomiasis) of the human 
host, where they can survive 3 to 5 years on average.
3 
The female produces tens to thousands of eggs a day, half of which 
become trapped in tissues such as the liver, the intestine or the bladder where they induce immune reactions and damage the 
organs. 
3
 This results in symptoms such as portal hypertension, bloody diarrhoea or anaemia, which can lead to developmental 
stunting in children.
2
 
 The exclusive treatment to date for schistosomiasis is praziquantel (PZQ). The drug is effective against all main schistosome 
species and is administered to affected populations in mass drug administration campaigns to prevent morbidity.
4
 However, 
there are several drawbacks associated with the use of PZQ, such as its lack of activity against juvenile worms or its low 
metabolic stability in vivo.
2,5
 Moreover, the use of only PZQ to treat and control millions of people raises the risk of PZQ-resistant 
schistosome strains. Reduced susceptibility of S. mansoni to PZQ was first reported in 1973 by Katz et al. in Brazil and sporadic 
treatment failures have been reported since then, although it is not known if they are due to drug resistance.
6,7
 Therefore, there 
is an urgent need to develop novel antischistosomal drug candidates with different modes of action.
8
 
 As de novo drug discovery is often a long and expensive process, a commonly employed strategy, especially for neglected 
tropical disease like schistosomiasis, is drug repurposing.
9
 This approach investigates already existing drugs as novel 
antischistosomal drug candidates.
9
 As schistosomiasis and malaria are often co-endemic, antimalarials have been explored for 
their antischistosomal activity.
10,11
 Moreover, many antimalarials are thought to target the heme detoxification pathway from 
hemoglobin digestion by the malaria-causing Plasmodium parasites, a pathway that also exists in the blood-feeding Schistosoma 
spp..
12
 In previous studies, mefloquine (Scheme 1), a well-known antimalarial drug,
13
 was identified as a potential 
antischistosomal drug candidate.
14
 Keiser et al. reported that mefloquine administered to mice infected with S. mansoni and S. 
japonicum showed promising antischistosomal properties. In the adult infection model, total and female worm burden 
reductions of 72-100% were achieved with a single dose of 200 mg/kg to 400 mg/kg. A single dose of 100 mg/kg to 400 mg/kg of 
mefloquine given to mice infected with juvenile stages of S. mansoni resulted in a high total and female worm burden reduction 
of 87% to 100% - an important result considering PZQ’s lack of activity against the juvenile stage. The promising in vivo results 
obtained with mefloquine were further investigated in clinical phase II trials, alone and in combination with PZQ.
15–17
 The 
authors, however, noted that antimalarial parent compounds should not be used in treatment campaigns, as they might increase 
the risk of resistant Plasmodium spp., which are faster mutating and have already demonstrated resistance to previous 
antimalarials. The investigation of potential derivatives has therefore been employed.
18
 
 With this in mind, our research groups have decided to derivatize mefloquine with various organometallic moieties. 
Organometallic compounds are defined as metal complexes bearing at least one direct metal-carbon bond.
19
 The derivatization 
of a known organic drug with organometallic moieties has already proven to be successful in various areas of medicinal 
chemistry.
19–28
 In 1997, Biot et al. synthesized ferroquine, a ferrocenyl derivative of the antimalarial drug chloroquine, which was 
 
 
active against both chloroquine-sensitive and chloroquine resistant Plasmodium falciparum, the most virulent Plasmodium 
spp..
29
,
30
 Interestingly, the incorporation of the ferrocene fragment brought an additional metal-specific mode of action: the 
favourable redox properties of the Fe(III)/Fe(II) core of ferrocene produced reactive oxygen species, which can increase toxicity 
to the parasite.
31–33
 In addition, the attachment of ferrocene enhanced the lipophilicity of the compound, as has been observed 
for previous ferrocene derivatives.
34
 In phase II trials, ferroquine was effective against chloroquine resistant P. falciparum, both 
as a monotherapy and in conjunction with artesunate.35 
 The promising results obtained with ferroquine drew interest in the development of other organometallic drug candidates. 
Especially, there has been a growing interest in the design of organometallic drug candidates as antischistosomal agents.
36–44
 To 
incorporate the drug repurposing strategy, the research focused mainly on structure-based optimization of already established 
drugs. The antimalarial agents chloroquine and its organometallic derivatives ferroquine, ruthenoquine and hydroxyl-ferroquine 
were analysed as potential antischistosomal agents by the groups of Biot, Keiser and Gasser.
11,14
 The organometallic compounds 
evaluated did not, however, increase the weak antischistosomal properties of the parent drug chloroquine in vivo (worm burden 
reduction of 11% for chloroquine and 19% for ferroquine at a dose of 200 mg/kg).
14,11
 
 Herein, we report two organometallic mefloquine derivatives, in which the piperidinyl group of the organic drug is replaced 
with a ferrocenyl or a ruthenocenyl moiety (Scheme 1). We describe their synthesis, characterization and antischistosomal 
activities against S. mansoni in vitro and in vivo and compare them to the parent drug mefloquine. We note that similar 
organometallic compounds were evaluated against malaria by Biot et al.
45
. Biot replaced the piperidinyl unit of mefloquine with 
a ferrocenyl moiety bearing an amine. He intended to mimic intramolecular hydrogen bonding of mefloquine, trying to adapt the 
pharmacokinetics of the organic drug. But the ferrocenyl compounds exhibited a lower antimalarial activity than the mefloquine 
itself. Also, these compounds have never been tested on schistosomiasis. As the precise mode of action of mefloquine for 
treating schistosomiasis is not yet understood, it is uncertain if this particular intramolecular hydrogen bonding is crucial. Thus, in 
this study, we intended to try a simple and efficient approach to repurpose an already known drug and testing metallocenyl 
derivatives of mefloquine for the time on adult-stage S. mansoni. 
 
 
 
 
Scheme 1 Schematic representation of newly designed organometallic derivatives of mefloquine, [2,8-bis(trifluoromethyl)quinolin-4-yl] ferrocenemethanol 
(3) and [2,8-bis(trifluoromethyl)quinolin-4-yl] ruthenocenemethanol (4). 
Results and Discussion 
Synthesis and characterization 
The ferrocenyl and ruthenocenyl analogues of mefloquine were prepared in a one-step reaction procedure, starting from in situ 
generated 2 reacting directly with the respective metallocenecarboxaldehyde, as presented in Scheme 2. Both organometallic 
derivatives 3 and 4 were isolated as racemates (See ESI, Figure S9 and S10). We have decided to evaluate the racemic mixtures 
first in our in vitro and in vivo studies in order to obtain initial insights into their potential antischistosomal properties. 
 The first step in the synthesis of the desired organometallic analogues is the lithiation of 2,8-bis-(trifluoromethyl)-4-
bromoquinoline 1 with 
n
BuLi. The resulting activated quinolone 2 reacted directly in situ with the ferrocenecarboxaldehyde 3a to 
obtain [2,8-bis(trifluoromethyl)quinolin-4-yl] ferrocenemethanol 3 in 94% yield. In order to improve our understanding of the 
 
 
possible redox-based mode of action of the ferrocene moiety, we also synthesized the corresponding ruthenocenyl analogue (4) 
of 3. Although both ferrocene and ruthenocene are isoelectronic and have a similar geometry and steric demand, they have a 
different electrochemical behaviour and redox properties. The ruthenocenecarboxaldehyde was synthesized following the 
literature procedure of Sanders et al.
46
 Compound 4 was prepared in a similar fashion as 3, where the in situ generated 2 was 
reacted directly with ruthenocenecarboxaldehyde (Scheme 2). [2,8-bis(trifluoromethyl)quinolin-4-yl] ruthenocenemethanol 4 
was obtained in 78% yield. The ferrocenyl- and ruthenocenyl- analogues of mefloquine (3 and 4) were characterized by 
1
H, 
13
C, 
19
F NMR spectroscopies, high-resolution ESI-mass spectrometry and their purity was confirmed by elemental analysis. 
 
 
 
Scheme 2 Reagents and conditions: (i) nBuLi, dry Et2O, 20 min, -78 °C; (ii) ferrrocenecarboxaldehyde (3a), dry Et2O, 1 h, -78 °C, 94%; (iii) 
ruthenocenecarboxaldehyde (4a), dry Et2O, 1 h, -78 °C, 78%. 
Biological evaluation 
In vitro activity against adult S. mansoni and cytotoxicity against mammalian cell lines. The biological efficacy of the metallocene  
derivatives 3 and 4 were evaluated against S. mansoni, together with mefloquine, which was used as a reference compound. All 
drugs showed similar activity, with IC50 values of 3.3, 4.0 and 3.5 µM for 3. 4 and mefloquine, respectively after 72 h incubation 
(Table 1). 
 With the demonstrated in vitro antischistosomal activity of 3 and 4, we were eager to investigate the selectivity of the 
compounds toward parasites. Therefore, we evaluated the cytotoxicity of 3 and 4 using three mammalian cell lines: a cervical 
cancer cell line (HeLa), a noncancerous human retinal pigmented epithelial cell line (RPE-1) and a noncancerous mouse liver cell 
line (TIB-75), to determine the selectivity of our compounds. The results obtained are summarized in Table 1. The two 
compounds 3 and 4 were moderately cytotoxic to HeLa cells with IC50 values of 36.6 ± 1.0 and 31.6 ± 0.8 µM, respectively. 
Similarly, moderate toxicity was observed for 3 and 4 in RPE-1 cells (IC50 = 81.4 ± 3.5, 49.7 ± 4.8 µM, respectively). However, TIB-
75 cells are more susceptible to 3 and 4 than noncancerous REP-1 and cancerous HeLa cell lines with IC50 values of 22.1 ± 1.0 and 
6.2 ± 0.4 µM, respectively. Importantly, our two compounds were found to have lower toxicity in all cell lines than mefloquine 
itself (IC50 = 4.7 ± 0.2, 11.1 ± 0.4, and 4.1 ± 0.1 µM, respectively). 
 In vivo activity against adult S. mansoni. With the encouraging in vitro results, we progressed compounds 3 and 4 to in vivo 
studies, with mefloquine as a reference, in a patent S. mansoni-mouse model (Table 2). 
 
Table 1. In vitro activity of mefloquine derivatives 3 and 4 as compared to mefloquine against S. mansoni adult worms and cytotoxicity against HeLa, RPE-1 and TIB-75 cells. 
Compound 
IC50 value [µM] 
S. mansoni HeLa RPE-1 TIB-75 
3 3.3 
+0.0
 37 
± 1.0
 81 
± 3.5
 22 
± 1.0
 
4 4.0 
+0.1
 32 
± 0.8
 50 
± 4.8
 6.2 
± 0.4
 
Mefloquine 3.5 
+0.0
 4.7 
± 0.2
 11 
± 0.4
 4.1 
± 0.1
 
 
 The ferrocene derivative 3 indicated no activity with a single oral 200 mg/kg dose while the total worm burden reduction for 
the ruthenocene derivative 4 was 27.4%. For comparison, at 200 mg/kg, mefloquine achieved total worm clearance in S. 
mansoni-infected mice. 
 
Thus, a single oral 200 mg/kg dose (curative dose for mefloquine) yielded weak antischistosomal activity from compound 4 in 
vivo. The good antischistosomal activity in vitro but the lack of activity in vivo might be explained by any number of host 
processes. We subsequently tested if protein binding might reduce drug efficacy by repeating the adult S. mansoni in 
vitro assay with physiological (45g/L) concentration of albumin. The efficacy was lowered for all 3 compounds, but more: IC50 
values increased to 25 µM for mefloquine, 65 µM for compound 3 and >>100 µM for compound 4. The higher values of 3 and 4 
as compared to mefloquine might provide a hint to their lowered efficacy, though likely there are additional reasons,  which may 
 
 
include  poor absorption, high protein binding, inactivation of the drug along the metabolic route or a very fast clearance of the 
drug in vivo. We note also that since the doses are in mg/kg, the actual amount of organometallic compound given to the mice is 
inferior by 28% compared to the organic compound. 
 Additionally, one mouse treated with compound 3 died a few days after treatment revealing severe damage to the liver at 
dissection. Surprisingly, this occurred even though derivative 3 was shown to be the least toxic against the TIB-75 liver cell line. 
Further structure-activity relationship and pharmacokinetic data would be required to fully understand the in vivo results. 
Conclusions 
Facing the urgent need to develop new drug candidates against schistosomiasis, two organometallic compounds, [2,8-
bis(trifluoromethyl)quinolin-4-yl] ferrocenemethanol (3) and [2,8-bis(trifluoromethyl)quinolin-4-yl] ruthenocenemethanol (4) 
were synthesized. These candidates are derivatives of mefloquine, a well-known antimalarial agent also known for its 
antischistosomal activity. These new compounds were shown to be moderately cytotoxic to mammalian cell lines, although less 
cytotoxic than mefloquine itself, and thereby show selective activity on parasites. Their activities against S. mansoni were 
compared to mefloquine. The in vitro activities against adult S. mansoni were equivalent to mefloquine. However, the 
organometallic compounds showed only weak antischistosomal
Table 2. Effect on worm burden of single oral doses (200 mg/kg) of mefloquine derivatives 3 and 4 and mefloquine in adult stage S. mansoni-infected mice. 
Compound Dose (mg/kg) No. of mice 
Worm Burden Worm Burden Reduction (%) 
Female Total Female Total 
Control Untreated 8 23 46 - - 
3 200 3
a
 41 81 0 0 
4 200 4 17 34 28 27 
Mefloquine 200 4 0 0 100 100 
a 
One mouse died prematurely
 
 
properties in vivo. The results obtained suggest that derivatization of mefloquine may be a possible avenue for 
drug repositioning against schistosomiasis, however studies with additional derivatives would be required to 
optimize in vivo activity. 
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